G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Regional Quality Manager - Pharmaceutical Diagnostics, ANZ

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Sydney NSW, Australia
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Advanced experience in Quality Assurance, Healthcare Quality, Pharmaceutical Quality, Medical Device Quality, Life Sciences, or other regulated healthcare environments.
  • Knowledge level comparable to a Bachelor's degree from an accredited university or college in Pharmacy, Science, Engineering, Healthcare, Quality Management, Life Sciences, or a related technical discipline, or an equivalent combination of education and relevant experience.
  • Demonstrated knowledge of Quality Management Systems, Good Distribution Practice, risk management, Corrective and Preventive Actions, investigations, auditing, change control, training systems, supplier quality management, and regulatory compliance.
  • Working knowledge of pharmaceutical, radiopharmaceutical, healthcare, medical device, or regulated distribution requirements applicable to Australia and New Zealand.
  • Ability to interpret regulatory requirements and translate them into compliant operational processes.
  • Experience working within a matrix organization and collaborating effectively across multiple functions and geographies.
  • Strong problem-solving, decision-making, and risk-based thinking capabilities.
  • Ability to influence stakeholders and drive compliance and quality objectives within cross-functional teams.
Responsibilities
  • Establish, maintain, and continuously improve the Pharmaceutical Diagnostics Quality Management System across Australia and New Zealand, ensuring alignment with global quality requirements and local regulatory obligations.
  • Drive quality culture and compliance through effective quality objectives, metrics, management review processes, reporting mechanisms, and continuous improvement initiatives.
  • Serve as the designated Quality representative for Pharmaceutical Diagnostics operations in Australia and New Zealand and as the primary quality contact for internal and external stakeholders.
  • Ensure ongoing compliance with Therapeutic Goods Administration requirements, Medsafe requirements, Good Distribution Practice requirements, and other relevant regulatory authorities.
  • Lead regulatory inspection readiness and represent the organization during inspections, audits, regulatory inquiries, and authority communications.
  • Manage quality systems including Quality Events, Investigations, Corrective and Preventive Actions, Change Controls, Risk Management, Training, Documentation, Supplier Quality, and Audit Management.
  • Provide quality oversight and approval within established authority levels for quality records, investigations, risk assessments, Corrective and Preventive Actions, deviations, and change controls.
  • Ensure timely investigation, escalation, and resolution of quality and compliance issues using risk-based decision-making principles.
  • Lead Good Distribution Practice compliance across Australia and New Zealand, overseeing customer service, warehousing, transportation, distribution activities, and third-party logistics providers.
  • Ensure distributors, service providers, contract partners, and other relevant third parties are qualified, monitored, and managed in accordance with company and regulatory requirements.
  • Support product disposition decisions, product holds, recalls, field actions, complaints, market actions, and business continuity activities impacting the Australia and New Zealand market.
  • Lead and support internal audits, supplier audits, self-inspections, and regional quality assessments, and ensure identified findings are remediated and closed.
  • Maintain inspection and audit readiness by ensuring quality systems, records, and personnel remain compliant and prepared for regulatory review.
  • Partner with Regulatory Affairs, Supply Chain, Customer Service, Commercial Operations, Pharmacovigilance, and Global Quality to ensure compliant business operations and effective risk management.
  • Monitor and analyze quality performance indicators, audit trends, compliance risks, customer feedback, Corrective and Preventive Action effectiveness, and other quality metrics to identify improvement opportunities.
  • Provide quality leadership, coaching, mentoring, and technical guidance to colleagues and cross-functional teams, influencing decisions through expertise and collaboration.
  • Lead or participate in regional and global quality projects, process improvement initiatives, and quality transformation activities.
  • Act as an escalation point for significant quality, regulatory, patient safety, or business continuity risks impacting the Australia and New Zealand region.
  • Operate with autonomy within established quality policies, procedures, and operating mechanisms, applying technical expertise, analytical thinking, and sound judgment to solve complex quality and compliance challenges, influence stakeholders, and drive business results.
Desired Qualifications
  • Strong understanding of GE HealthCare Quality principles, Pharmaceutical Diagnostics Quality Management Systems, GxP requirements, Good Distribution Practice, and regulated healthcare operations.
  • Familiarity with Therapeutic Goods Administration requirements, Medsafe expectations, and Australia and New Zealand healthcare regulatory frameworks.
  • Experience interacting with regulatory authorities, inspectors, customers, and external auditors.
  • Demonstrated experience leading audits, inspections, supplier quality activities, and quality system improvement programs.
  • Ability to communicate effectively across all levels of the organization, orally and in writing.
  • Ability to analyze data, identify trends, solve complex problems, and implement sustainable corrective actions.
  • Project management, change management, and continuous improvement skills.
  • Ability to document, plan, prioritize, market, and execute quality and compliance programs successfully.
  • Ability to coach, mentor, and influence individuals and teams without direct authority.
  • Experience with electronic Quality Management Systems, document management systems, and digital quality tools.
  • Ability to balance regulatory compliance, business objectives, operational efficiency, and customer needs.
  • High degree of integrity, accountability, customer focus, and commitment to patient safety and product quality.
  • Lead Auditor qualification or equivalent audit experience.
  • Experience supporting product recalls, field actions, inspections, regulatory submissions, or post-market quality activities.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.

Associated Press
Sep 22nd, 2026
GE HealthCare raises quarterly dividend 14% to $0.04 per share for Q3 2026

GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.